[HTML][HTML] Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
MFM Saleh, Y Saunthararajah - Clinical Case Reports, 2017 - ncbi.nlm.nih.gov
MFM Saleh, Y Saunthararajah
Clinical Case Reports, 2017•ncbi.nlm.nih.govPyoderma gangrenosum (PG) is a morbid necrotizing neutrophilic dermatoses for which
current treatments are inadequate. Here, we describe the use of a novel noncytotoxic
regimen of the deoxycytidine analog decitabine to treat underlying myeloid malignancy
causing PG, to thereby produce safe and effective resolution of extensive PG.
current treatments are inadequate. Here, we describe the use of a novel noncytotoxic
regimen of the deoxycytidine analog decitabine to treat underlying myeloid malignancy
causing PG, to thereby produce safe and effective resolution of extensive PG.
Pyoderma gangrenosum (PG) is a morbid necrotizing neutrophilic dermatoses for which current treatments are inadequate. Here, we describe the use of a novel noncytotoxic regimen of the deoxycytidine analog decitabine to treat underlying myeloid malignancy causing PG, to thereby produce safe and effective resolution of extensive PG.
ncbi.nlm.nih.gov
